Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Single Arm Open-Label Clinical Trial of Gavocabtagene Autoleucel (Gavo-cel) in Patients With Advanced Mesothelin-Expressing Cancer

NCT03907852 is registered in ClinicalTrials.gov with TCR2 Therapeutics as lead sponsor.

NCT NCT03907852
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03907852 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Single Arm Open-Label Clinical Trial of Gavocabtagene Autoleucel (Gavo-cel) in Patients With Advanced Mesothelin-Expressing Cancer
Lead sponsor
TCR2 Therapeutics
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
April 15, 2019
Completion date
November 2, 2028
Enrollment
57 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

cholangiocarcinoma, cholangiocarcinoma recurrent, high grade ovarian serous adenocarcinoma, mesothelioma, mesothelioma peritoneum, mesothelioma, malignant, mesothelioma; pleura, mesotheliomas pleural, non small cell lung cancer, non small cell lung cancer metastatic, ovarian cancer